ArticleThrombosis journal2026
Optimal timing of anticoagulation therapy for venous thromboembolism prevention after intracranial hemorrhage.
Article in Thrombosis journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThis study aimed to explore the optimal timing of anticoagulation initiation for the prevention of VTE in patients with ICH.
methodsThis retrospective cohort study enrolled consecutive patients in Nanjing Drum Tower Hospital and The Medical Information Mart for Intensive Care IV database in the United States who were diagnosed with ICH. The restricted cubic spline was fitted to explore the dose-response relationship between anticoagulation initiation time and clinical outcomes. Based on the identified inflection point, patients were stratified into the ≤ 2 days group and the >2 days group according to the timing of anticoagulant initiation. The primary outcome was a composite outcome of VTE and intracranial rebleeding events.
resultsA total of 3,841 patients were divided into ≤ 2 days group (n = 2047) and >2 days group (n = 1794). HRs for ≤ 2 days group and >2 days group of composite outcome, VTE and intracranial rebleeding events were 1.20 (1.02–1.43), 2.01 (1.59–2.55) and 0.68 (0.53–0.87). For the subgroup analysis, significant interactions were observed between gender, race, etiology, location of ICH, and treatment group for the composite outcome (P<0.05). Compared to the all other races, a difference was observed in the relationship between anticoagulation initiation time and outcome events in Asians.
conclusionsInitiating anticoagulation within 2 days of ICH can balance bleeding and thrombosis risks, and should be administered to patients of all races to optimize outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.